Posted On: 01/14/2015 7:45:41 PM
Post# of 30066
The thing I discovered about Nanosomix when I dug into them last week was that they were rushing to market, reliable testing be damned!! The problem with rushing to market too soon is that if you are shown to be unreliable....you're history! Gerald told me that way back in Las Vegas.
I think Gerald is choosing to move into RUO gently and is being careful about making promises about Lympro until they've tested more people.
I'm sure the univariant data is at least as good as what they published before, so I'm sure they'll get some pharmas to start using LymPro. Unfortunately, the shareholders were all programmed to analyze Lympro according to the multivariant sens and spec numbers and we all thought they had to be in the mid 90s. I don't think that is accurate. LymPro is still a valuable test with CD 19 alone, at least for Pharmas doing clinical trials.
When we open up Lympro to the general market through CLIA, we'll need those multivariant numbers in the 90s to induce people to take the test and feel it's findings are accurate. Gerald said we'll have those numbers when CLIA comes.
Let's see if we get more specifics on the LymPro data in a PR tomorrow. In truth though, I don't think pharmas care about using 5 or 6 biomarkers just to drive up the accuracy a few points. If CD 19 has "highly statistically significant results," I think Pharmas will start signing up.
I think Gerald is choosing to move into RUO gently and is being careful about making promises about Lympro until they've tested more people.
I'm sure the univariant data is at least as good as what they published before, so I'm sure they'll get some pharmas to start using LymPro. Unfortunately, the shareholders were all programmed to analyze Lympro according to the multivariant sens and spec numbers and we all thought they had to be in the mid 90s. I don't think that is accurate. LymPro is still a valuable test with CD 19 alone, at least for Pharmas doing clinical trials.
When we open up Lympro to the general market through CLIA, we'll need those multivariant numbers in the 90s to induce people to take the test and feel it's findings are accurate. Gerald said we'll have those numbers when CLIA comes.
Let's see if we get more specifics on the LymPro data in a PR tomorrow. In truth though, I don't think pharmas care about using 5 or 6 biomarkers just to drive up the accuracy a few points. If CD 19 has "highly statistically significant results," I think Pharmas will start signing up.
(0)
(0)
